Unity Biotechnology Inc (UBX) - Total Assets
Based on the latest financial reports, Unity Biotechnology Inc (UBX) holds total assets worth $30.35 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Unity Biotechnology Inc - Total Assets Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's total assets have evolved over time, based on quarterly financial data. Also see UBX company net worth for the company's overall valuation and market capitalisation.
Unity Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Unity Biotechnology Inc's total assets of $30.35 Million consist of 64.4% current assets and 35.6% non-current assets. Review UBX liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Unity Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Unity Biotechnology Inc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Unity Biotechnology Inc's current assets represent 64.4% of total assets in 2024, a decrease from 96.7% in 2016.
- Cash Position: Cash and equivalents constituted 20.1% of total assets in 2024, down from 92.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Unity Biotechnology Inc Competitors by Total Assets
Key competitors of Unity Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Vaxcyte Inc
NASDAQ:PCVX
|
USA | $3.14 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $1.11 Billion |
|
Chongqing Zhifei Bio Products
SHE:300122
|
China | CN¥29.09 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
China | CN¥6.82 Billion |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.16 Billion |
Unity Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.95 | 4.98 | 7.88 |
| Quick Ratio | 1.95 | 4.98 | 7.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.58 Million | $30.79 Million | $107.87 Million |
Unity Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Unity Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.59 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | -42.7% |
| Total Assets | $37.66 Million |
| Market Capitalization | $2.75 Million USD |
Valuation Analysis
Below Book Valuation: The market values Unity Biotechnology Inc's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Unity Biotechnology Inc's assets decreased by 42.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Unity Biotechnology Inc (2016–2024)
The table below shows the annual total assets of Unity Biotechnology Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $37.66 Million | -42.67% |
| 2023-12-31 | $65.69 Million | -47.17% |
| 2022-12-31 | $124.35 Million | -0.29% |
| 2021-12-31 | $124.71 Million | -20.22% |
| 2020-12-31 | $156.32 Million | +3.37% |
| 2019-12-31 | $151.22 Million | -16.63% |
| 2018-12-31 | $181.38 Million | +77.78% |
| 2017-12-31 | $102.02 Million | +5.56% |
| 2016-12-31 | $96.65 Million | -- |
About Unity Biotechnology Inc
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. Its lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develop… Read more